Congestive Heart Disease Marker Tes Research Report, Share, and Forecast to 2025Posted by rekha on October 16th, 2019 The global congestive heart disease marker tests market expected to reach US$ 4,326.8 Mn by 2025 owing to rise in prevalence of various cardiac diseases around the globe. For instance, according to World Health Organization, approximately 17.9 Mn deaths occurring due to cardiovascular diseases each year around the globe. Moreover, screening programs organized by government to increase the awareness about the cardiac diseases among the population, increase in the R&D investment for the development of innovative diagnostic tests, and sophisticated healthcare infrastructure in developing and developed countries are anticipated to propel the congestive heart disease marker tests market over the forecast years. However, high cost for the diagnostic tests, lack of advanced diagnostic techniques in low income countries, and stringent regulations for the test approval, are deter the congestive heart disease marker tests market over the forecast timeframe Global congestive heart disease marker tests market segmented on the basis of product type, technology, test type, application, end user, and region For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15832 Troponins Test Segment Dominate the Global Congestive Heart Disease Marker Tests Market Based on the test type, global congestive heart disease marker tests market segmented into myocardial muscle creatine kinase, myoglobin, troponins (T and I), ischemia modified albumin, NT-proBNP, and others. Among all the tests, troponin (T and I) segment dominated the global congestive heart disease marker tests market and the same trend is expected over the forecast years owing to high efficiency and accuracy of troponin test results compared with other diagnostic tests. Moreover, launch of advanced diagnostic tests such as point-of-care devices also boost the market over the forecast years. For instance, in June 2015, Roche launched CARDIAC point-of-care Troponin T test for the cobas h 232 system to diagnose the heart attack in patients. North America Leads the Global Congestive Heart Disease Marker Tests market PBI’s global Congestive Heart Disease Marker Tests market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing increase in the prevalence of cardiac diseases in U.S. and Canada. For instance, according to American college of cardiology 2017, approximately790,000 adults suffers from heart attack each year. Moreover, favorable reimbursement policies, increase in healthcare expenditure and presence of skilled professionals are bolster the market over the forecast years. Europe congestive heart disease marker tests market projected to exhibit significant growth due to adoption of technologically advanced diagnostic tests, rapid economic growth, and increase in healthcare expenditure are bolster the market Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market player Global Congestive Heart Disease Marker Tests market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In March 2017, Fujirebio Europe launched Lumipulse G hs Troponin I assay for use in the diagnosis of Acute Myocardial Infarction that provide precise and sensitive results in 35 minutes. Key player’s profiles in the report are Bio-Rad Laboratories, Inc., Siemens Healthineers, Roche Diagnostics, Fujirebio Europe, Becton, Dickinson and Company, Randox Laboratories Ltd., BioMerieux, Thermo Fisher Scientific, and Beckman Coulter Precision Business Insights (PBI) in its report titled “Global Congestive Heart Disease Marker Tests Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period Detailed Segmentation By Products o Reagents and Kits o Instruments o Software and Services By Technology o Chemiluminescence o Immunofluorescence o ELISA o Immunochromatography o Others By Test Type o Myocardial muscle Creatine Kinase (CK-MB) o Myoglobin o Troponins (T and I) o Ischemia Modified Albumin (IMA) o NT-proBNP or Brain Natriuretic Peptide (BNP) or o Others By Application o Myocardial Infarction o Acute Coronary Syndrome o Congestive Heart Failure o Atherosclerosis o Others By End User o Hospitals o Clinics o Diagnostic Centers o Others Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-congestive-heart-disease-marker-tests-market/ Like it? Share it! More by this author |